Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. (Q48050678)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29071761%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

title

Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29071761%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29071761%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

author name string

P S Chowdhury

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29071761%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

K Chamoto

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29071761%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

language of work or name

English

0 references

publication date

16 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29071761%20AND%20SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

8 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29071761%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

volume

283

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29071761%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29071761%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

page(s)

110-120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29071761%20AND%20SRC:MED&resulttype=core&format=json

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

8 April 2020

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1002/J.1460-2075.1992.TB05481.X

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

VEGF as a mediator of tumor-associated immunodeficiency

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Immunologic correlates of the abscopal effect in a patient with melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Clinical significance of T cell metabolic reprogramming in cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Combination immunotherapy: a road map.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Vascular endothelial growth factor is a secreted angiogenic mitogen

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Systemic effects of local radiotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

An immunogenic personal neoantigen vaccine for patients with melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Metabolism, migration and memory in cytotoxic T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Targeting T Cell Co-receptors for Cancer Therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Agonist antibodies to TNFR molecules that costimulate T and NK cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Combining radiotherapy and cancer immunotherapy: a paradigm shift

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Hepatotoxicity with combination of vemurafenib and ipilimumab

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Evolution of oncolytic viruses: novel strategies for cancer treatment

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

T cell metabolic fitness in antitumor immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Regulation and function of mTOR signalling in T cell fate decisions

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

T cell metabolism drives immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Current clinical trials testing the combination of immunotherapy with radiotherapy.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Inhibition of T cell proliferation by macrophage tryptophan catabolism

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Combination cancer immunotherapy and new immunomodulatory targets

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Chemoimmunotherapy: reengineering tumor immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Diisopropylamine dichloroacetate, a novel pyruvate dehydrogenase kinase 4 inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan failure in severe influenza

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Vascular endothelial growth factor: much more than an angiogenesis factor

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

PD-1 and its ligands in tolerance and immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Lymphocytic infiltration and survival in rectal cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Targeting T cell metabolism for therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Immune parameters affecting the efficacy of chemotherapeutic regimens

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Oncolytic virotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Thunder and lightning: immunotherapy and oncolytic viruses collide

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

OX40 is a potent immune-stimulating target in late-stage cancer patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Elements of cancer immunity and the cancer-immune set point

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

AMPK: a metabolic switch for CD8+ T-cell memory.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Emerging concepts of T cell metabolism as a target of immunotherapy.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1111/JOIM.12708

Identifiers

DOI

10.1111/JOIM.12708

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29071761%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

1 reference